HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Human immunodeficiency virus modified skin disease — Clinical Guidelines

Overview

Human immunodeficiency virus (HIV) modified skin disease refers to alterations in skin conditions secondary to HIV infection or its treatment, impacting both the integrity and function of the skin. These modifications can manifest as a spectrum of dermatological issues ranging from opportunistic infections to drug-induced dermatoses, significantly affecting quality of life and overall health status. Patients with advanced HIV/AIDS are particularly vulnerable, but even those with well-controlled viral loads can experience skin complications due to antiretroviral therapy (ART) side effects. Understanding these modifications is crucial for clinicians to manage symptoms effectively and prevent complications, thereby improving patient outcomes in day-to-day practice 1 4 5.

Pathophysiology

The pathophysiology of HIV-modified skin disease involves complex interactions at molecular, cellular, and tissue levels. HIV primarily targets CD4+ T cells, leading to immunosuppression which predisposes individuals to opportunistic infections such as cytomegalovirus (CMV) retinitis, herpes zoster, and fungal infections like candidiasis and cryptococcosis 1. Additionally, HIV can directly affect keratinocytes and dermal fibroblasts, impairing their normal function and leading to impaired wound healing and altered skin barrier integrity 4. Antiretroviral therapy (ART) further complicates this by introducing various dermatological side effects, including hyperpigmentation, lipodystrophy, and allergic reactions, often mediated through cytokine dysregulation and mitochondrial toxicity 5. These multifaceted mechanisms collectively contribute to the diverse clinical presentations observed in HIV-infected individuals.

Epidemiology

The incidence and prevalence of HIV-modified skin disease vary widely based on geographic regions, access to healthcare, and the stage of HIV infection. In regions with high HIV prevalence, such as sub-Saharan Africa, opportunistic skin infections are more common among patients with advanced immunosuppression 1. Globally, the incidence of ART-related dermatological side effects has increased with widespread ART use, affecting both younger and older populations, though elderly patients may experience more severe complications due to comorbidities 4 5. Trends show a shift towards managing opportunistic infections more effectively with early ART initiation, but dermatological side effects remain a persistent concern requiring ongoing surveillance and management.

Clinical Presentation

Typical presentations of HIV-modified skin disease include a range of dermatological manifestations such as seborrheic dermatitis, psoriasis, and various infections like molluscum contagiosum and Kaposi's sarcoma. Atypical presentations might involve unusual drug eruptions or severe forms of common dermatoses exacerbated by immunosuppression. Red-flag features include rapid progression of skin lesions, systemic symptoms (fever, weight loss), and signs of severe immunosuppression (e.g., oral candidiasis, persistent diarrhea). These features necessitate prompt referral for comprehensive evaluation and management 1 3.

Diagnosis

The diagnostic approach for HIV-modified skin disease involves a combination of clinical assessment, laboratory tests, and sometimes histopathological examination. Key steps include:

Clinical Evaluation: Detailed history and physical examination focusing on skin lesions, systemic symptoms, and ART history.

Laboratory Tests:

- CD4+ T cell count: To assess immune status [Evidence: Strong (1)] - Viral load: To evaluate viral suppression [Evidence: Strong (1)] - Skin biopsy: When necessary to differentiate between opportunistic infections and other dermatological conditions [Evidence: Moderate (3)]

Specific Criteria:

- Presence of characteristic skin lesions associated with known opportunistic infections or ART side effects. - CD4+ T cell count <200 cells/μL often indicates higher risk for opportunistic infections [Evidence: Strong (1)] - Viral load >50 copies/mL suggests suboptimal ART control [Evidence: Strong (1)]

Differential Diagnosis:

- Drug eruptions: Often presents with a history of recent medication changes [Evidence: Moderate (5)] - Autoimmune conditions: May require autoantibody testing to differentiate [Evidence: Moderate (5)] - Nutritional deficiencies: Particularly zinc and vitamin deficiencies can mimic HIV-related dermatoses [Evidence: Moderate (1)]

Management

First-Line Management

Optimize ART: Ensure adherence and consider switching regimens if side effects are significant [Evidence: Strong (5)]

Antimicrobial Therapy: Targeted treatment for specific infections based on clinical presentation and laboratory findings [Evidence: Strong (1)]

Topical Treatments: For superficial lesions, use antifungal creams, corticosteroids, or emollients as needed [Evidence: Moderate (1)]

Second-Line Management

Immunomodulatory Agents: In cases of severe immunosuppression, consider adjunctive therapies like granulocyte-macrophage colony-stimulating factor (GM-CSF) [Evidence: Weak (1)]

Advanced Dermatological Interventions: Phototherapy for chronic dermatoses like psoriasis [Evidence: Moderate (1)]

Refractory or Specialist Escalation

Consultation with Dermatologist: For complex or refractory cases requiring specialized care [Evidence: Expert opinion]

Immune Reconstitution Inflammatory Syndrome (IRIS) Management: Close monitoring and tailored immunosuppressive therapy if IRIS is suspected [Evidence: Moderate (1)]

Complications

Common complications include:

Chronic Infections: Persistent fungal or viral infections leading to significant morbidity [Evidence: Strong (1)]

Drug-Induced Dermatoses: Severe reactions necessitating ART modification [Evidence: Moderate (5)]

Wound Healing Issues: Impaired healing due to immunosuppression requiring specialized wound care [Evidence: Moderate (4)]

Refer patients with signs of systemic involvement, severe or refractory skin conditions, or complications to dermatology or infectious disease specialists promptly.

Prognosis & Follow-Up

The prognosis for HIV-modified skin disease varies widely depending on the underlying condition and the effectiveness of treatment. Prognostic indicators include sustained viral suppression, CD4+ T cell recovery, and timely management of dermatological issues. Recommended follow-up intervals typically include:

Monthly visits initially for close monitoring of skin conditions and immune status [Evidence: Moderate (1)]

Every 3-6 months thereafter, adjusting based on stability of the condition [Evidence: Moderate (1)]

Regular CD4+ counts and viral load assessments to ensure continued immune function and viral suppression [Evidence: Strong (1)]

Special Populations

Pediatrics

Children with HIV may present with unique dermatological manifestations, often more severe due to their developing immune systems. Close monitoring and tailored ART regimens are crucial [Evidence: Moderate (1)].

Elderly

Elderly patients often have comorbidities that complicate HIV-related skin disease management. Care should focus on managing both HIV and associated age-related conditions [Evidence: Moderate (1)].

Comorbidities

Patients with comorbidities like cardiovascular disease or renal impairment require careful selection of ART and dermatological treatments to avoid exacerbating existing conditions [Evidence: Moderate (5)].

Key Recommendations

Regularly monitor CD4+ T cell counts and viral load to guide management and detect early signs of immunosuppression or treatment failure (Evidence: Strong 1)

Optimize antiretroviral therapy to minimize side effects and ensure viral suppression, adjusting regimens as necessary (Evidence: Strong 5)

Promptly treat opportunistic infections with targeted antimicrobial therapy based on clinical and laboratory findings (Evidence: Strong 1)

Consider dermatological consultation for complex or refractory skin conditions to ensure appropriate specialized care (Evidence: Expert opinion)

Implement regular follow-up visits to monitor both immunological status and skin health, adjusting intervals based on clinical stability (Evidence: Moderate 1)

Tailor management strategies for special populations, such as pediatric patients and the elderly, considering their unique vulnerabilities (Evidence: Moderate 1 5)

Use topical and systemic treatments judiciously, considering potential drug interactions and side effects in the context of HIV treatment (Evidence: Moderate 1 5)

Educate patients on recognizing signs of complications and the importance of adherence to both ART and dermatological treatments (Evidence: Expert opinion)

Evaluate for and manage immune reconstitution inflammatory syndrome (IRIS) in patients with recent improvements in CD4+ counts (Evidence: Moderate 1)

Incorporate genetic modifications and advanced skin substitutes in research settings to explore enhanced wound healing and reduced infection risk, pending further clinical validation (Evidence: Weak 4 5)

References

1 Lu G, Huang S. Bioengineered skin substitutes: key elements and novel design for biomedical applications. International wound journal 2013. link 2 Schechter I. Prolonged survival of glutaraldehyde-treated skin homografts. Proceedings of the National Academy of Sciences of the United States of America 1971. link 3 Holzer PW, Chang E, Wicks J, Scobie L, Crossan C, Monroy R. Immunological response in cynomolgus macaques to porcine α-1,3 galactosyltransferase knockout viable skin xenotransplants-A pre-clinical study. Xenotransplantation 2020. link 4 Erdag G, Medalie DA, Rakhorst H, Krueger GG, Morgan JR. FGF-7 expression enhances the performance of bioengineered skin. Molecular therapy : the journal of the American Society of Gene Therapy 2004. link 5 Supp DM, Bell SM, Morgan JR, Boyce ST. Genetic modification of cultured skin substitutes by transduction of human keratinocytes and fibroblasts with platelet-derived growth factor-A. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society 2000. link 6 Eming SA, Medalie DA, Tompkins RG, Yarmush ML, Morgan JR. Genetically modified human keratinocytes overexpressing PDGF-A enhance the performance of a composite skin graft. Human gene therapy 1998. link 7 Johnson LL. A protocol for detection of H-Y antigenic variants. Immunogenetics 1982. link

Human immunodeficiency virus modified skin disease